Does DUPILUMAB Cause Tonsillar hypertrophy? 39 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Tonsillar hypertrophy have been filed in association with DUPILUMAB (Dupixent). This represents 0.0% of all adverse event reports for DUPILUMAB.
39
Reports of Tonsillar hypertrophy with DUPILUMAB
0.0%
of all DUPILUMAB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Tonsillar hypertrophy From DUPILUMAB?
Of the 39 reports, 2 (5.1%) required hospitalization.
Is Tonsillar hypertrophy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DUPILUMAB. However, 39 reports have been filed with the FAERS database.
What Other Side Effects Does DUPILUMAB Cause?
Pruritus (44,279)
Dermatitis atopic (33,670)
Product use in unapproved indication (33,452)
Rash (30,895)
Injection site pain (27,799)
Drug ineffective (23,712)
Dry skin (20,239)
Eczema (20,020)
Product dose omission issue (18,189)
Condition aggravated (16,459)
What Other Drugs Cause Tonsillar hypertrophy?
ADALIMUMAB (151)
ONDANSETRON (51)
SOMATROPIN (43)
SECUKINUMAB (42)
METHOTREXATE (39)
INFLIXIMAB (31)
TACROLIMUS (26)
INFLIXIMAB-DYYB (25)
ETANERCEPT (24)
LAMOTRIGINE (24)
Which DUPILUMAB Alternatives Have Lower Tonsillar hypertrophy Risk?
DUPILUMAB vs DURAGESIC
DUPILUMAB vs DUROGESIC
DUPILUMAB vs DUROTEP MT
DUPILUMAB vs DURVALUMAB
DUPILUMAB vs DUTASTERIDE